Evidence map›Paper›PMID 30208113›Full record

ArticlePloS one2018

Prolonging culture of primary human keratinocytes isolated from suction blisters with the Rho kinase inhibitor Y-27632.

Erik D Anderson, Inka Sastalla, Noah J Earland, Minai Mahnaz, Ian N Moore, Francisco Otaizo-Carrasquero, Timothy G Myers, Christopher A Myles, Sandip K Datta, Ian A Myles

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Therapeutic responses toScience translational medicine · 2020
    Trial
  2. Article
  3. Rho Kinases in Embryonic Development and Stem Cell Research.Archivum immunologiae et therapiae experimentalis · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Erik D AndersonLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.
Inka SastallaLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.
Noah J EarlandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.
Minai MahnazComparative Medicine Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, United States of America.
Ian N MooreComparative Medicine Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, United States of America.
Francisco Otaizo-CarrasqueroGenomic Technologies Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.
Timothy G MyersGenomic Technologies Section, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0002-7059-5906
Christopher A MylesAmmnRa Creations Engineering, San Jose, CA, United States of America.
Sandip K DattaLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0003-0243-7815
Ian A MylesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0001-9316-3703
National Institutes of Health · US

Funding

Host Immunity Against BacteriaZIAAI001043 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MYLES, IAN · 2009 to 2025
$18.9M
6 · The paper itself

Abstract

Keratinocytes are the most abundant cell type in the epidermis. They prevent desiccation and provide immunological and barrier defense against potential pathogens such as Staphylococcus aureus and Candida albicans. The study of this first line of immune defense may be hindered by invasive isolation methods and/or improper culture conditions to support stem cell maintenance and other potential mechanisms contributing to long-term subcultivation in vitro. Primary keratinocytes have been successfully isolated from blister roofs induced by negative pressure, which separates the epidermis from the dermis in vivo in human subjects. This method allows collection of pure epidermal cells without dermal contamination in a minimally invasive manner. However, the isolated keratinocytes differentiate and senesce when cultured in vitro beyond five passages. Here, we present evidence that the Rho kinase (ROCK) inhibitor Y-27632 can be used to effectively increase the proliferative capabilities of keratinocytes isolated using the suction blister method, similar to what has been previously reported for primary keratinocytes isolated using alternative methods. We show that the increase in passage number is directly correlated to delayed differentiation, and that cells passaged long term with the inhibitor retain their ability to stratify in organotypic raft cultures and respond to cytokine treatment; additionally, the late passage cells have a heterogeneous mix of differentiated and non-differentiated cells which may be predicted by a ratio of select differentiation markers. The described method presents a minimally invasive procedure for keratinocyte isolation and prolonged culture that allows analysis of keratinocyte function in both healthy volunteers and patients with dermatologic diseases.

Indexed as

AmidesBlisterCell Culture TechniquesCell ProliferationCells, CulturedEpidermisHumansKeratinocytesPyridinesrho-Associated KinasesAmidesPyridinesrho-Associated KinasesY 27632

Identifiers

PMID30208113
PMCPMC6135349
OpenAlexW2892266199

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.